By Fineline Cube China’s National Medical Products Administration (NMPA), in coordination with the Ministry of Public Security and the National Health Commission, announced the addition of three compounds—methoxyethyl etomidate, loretomidate, and solriamfetol—to the List of Medicinal Psychotropic Substances, effective 1 October 2026.
Regulatory Action Summary
| Item | Detail |
|---|---|
| Agencies | NMPA, Ministry of Public Security, National Health Commission |
| Action | Addition to List of Medicinal Psychotropic Substances |
| Substances Added | Methoxyethyl etomidate, Loretomidate, Solriamfetol |
| Effective Date | 1 October 2026 |
| Legal Basis | Regulations on Narcotic Drugs and Psychotropic Substances |
| Exemptions | Pharmaceutical preparations containing methoxyethyl etomidate or loretomidate already approved for marketing in China |
Substance Profiles & Clinical Context
- Methoxyethyl etomidate: A short-acting intravenous anesthetic agent derived from etomidate, used primarily for procedural sedation and induction of anesthesia.
- Loretomidate: A structural analog of etomidate developed as a potential alternative with modified pharmacokinetic properties and potentially reduced adrenocortical suppression.
- Solriamfetol: A dopamine and norepinephrine reuptake inhibitor approved in some markets for the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
The regulatory bodies cited concerns about potential misuse, diversion, and public health implications as key factors driving the classification decision. The move aligns China’s controlled substances framework with international monitoring practices for these compounds.
Implementation Timeline & Industry Impact
Pharmaceutical manufacturers and distributors will have until 30 September 2026 to adjust their compliance protocols, inventory management systems, and prescription verification processes to accommodate the new classification.
Companies holding marketing authorization for products containing methoxyethyl etomidate or loretomidate are exempt from the new restrictions, ensuring continuity of care for patients currently using these approved formulations.
Healthcare providers will need to update their prescribing practices for any non-exempt formulations containing these substances after the effective date, implementing stricter documentation and dispensing requirements consistent with other Schedule II psychotropic medications in China.
Market Implications
- Supply Chain: Distributors must implement enhanced tracking and security measures for these substances beginning 1 October 2026.
- Research Sector: Academic and clinical researchers will face additional regulatory hurdles when seeking approval for studies involving these compounds.
- International Alignment: The decision reflects China’s ongoing efforts to harmonize its controlled substances regulations with international standards, particularly those established by the International Narcotics Control Board.
Forward‑Looking Statements
This brief contains information regarding regulatory actions by Chinese authorities. Actual implementation may be subject to further guidance or administrative interpretations issued by the relevant agencies prior to the effective date.-Fineline Info & Tech